lunes, 23 de junio de 2025

Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing The data informed Amgen’s decision to use a slow titration schedule going forward in Phase 3

https://www.statnews.com/2025/06/23/amgen-maritide-obesity-drug-trial-discontinuations-side-effects-dosing-changes/

No hay comentarios:

Publicar un comentario